Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

• मुख्य लेखकों: Julián Olalla (लेखक), Javier Pérez-Stachowski (लेखक), Begoña Tortajada (लेखक), Alfonso Del Arco (लेखक), Efrén Márquez (लेखक), Javier De la Torre (लेखक), Miriam Nieto (लेखक), José María García de Lomas (लेखक), José Luis Prada (लेखक), Javier García-Alegría (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: BMC, 2018-10-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Background Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. Met...